High affinity binding of [3H]epibatidine to rat brain membranes

NeuroReport

Volumn 10, Issue 8, 1999, Pages 1631-1636

  Gnädisch, Daniela ^a   London, Edythe D ^a   Terry, Phyllis ^a   Hill, Geraldine R ^a   Mukhin, Alexey G ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Affinity; Cytisine; Epibatidine; Nicotine; Nicotinic acetylcholine receptor; Receptor binding

Indexed keywords

2 (2 IODO 5 PYRIDYL) 7 AZABICYCLO[2.2.1]HEPTANE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; CHOLINERGIC RECEPTOR AFFECTING AGENT; CYTISINE; EPIBATIDINE; NICOTINE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CHOLINERGIC SYSTEM; DRUG RECEPTOR BINDING; LIGAND BINDING; MALE; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

EID: 0033519593     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199906030-00002     Document Type: Article

References (26)

1. 1. Perry EK, Morris CM, Court JA et al. Neuroscience 64, 385-395 (1995).
2. 2. Schroder H, Giacobini E, Wevers A et al. Nicotinic receptors in Alzheimer's disease. In: Domino EF, ed. Brain Imaging of Nicotine and Tobacco. Ann Arbor, MI: NPP Books, 1995: 73-93.
3. 3. Horti A, Scheffel U, Stathis M et al. J Nucl Med 38, 1260-1265 (1997).
4. 4. Davila-Garcia MI, Musachio JL, Perry DC et al. J Pharamcol Exp Ther 282, 445-451 (1997).
5. 5. Abreo MA, Lin NH, Garvey DS et al. J Med Chem 39, 817-825 (1996).
6. 6. Holladay MW, Wasicak JT, Lin NH et al. J Med Chem 41, 407-412 (1998).
7. 7. Houghtling RA, Davila-Garcia MI, Hurt SD et al. Med Chem Res 4, 538-546 (1994).
8. 8. Houghtling RA, Davila-Garcia MI and Kellar KJ. Mol Pharmacol 48, 280-287 (1995).
9. 9. Marks MJ, Smith KW and Collins AC. J Pharamcol Exp Ther 285, 377-386 (1998).
10. 10. Sihver W, Gillberg PG and Nordberg A, Neuroscience 85, 1121-1133 (1998).
11. 11 Whiteaker P, Sharples CG and Wonnacott S. Mol Pharmacol 53, 950-962 (1998).
12. 12. Pabreza LA, Dhawan S and Kellar KJ. Mol Pharmacol 39, 9-12 (1991).
13. 13. Flores CM, Rogers SW, Pabreza LA et al. Mol Pharmacol 41, 31-37 (1992).
14. 14. Badio B and Daly JW. Mol Pharmacol 45, 563-569 (1994).
15. 15. Dukat M, Damaj MI, Glassco W et al. Med Chem Res 4, 131-139 (1993).
16. 16 Qian C, Li T, Shen TY et al. Eur J Pharmacol 250, R13-R14 (1993).
17. 17. Sullivan JP, Decker MW, Brioni JD et al. J Pharamcol Exp Ther 271, 624-631 (1994).
18. 18. Badio B, Garratfo HM, Spande TF et al. Med Chem Res 4, 131-139 (1993).
19. 19. Musachio JL, Horti A, London ED et al. J Labelled Comp Radiopharm 39, 39-48 (1997).
20. 20. Koron AO, Horti AG, Mukhin AG et al. J Med Chem 41, 3690-3698 (1998).
21. 21. Perry DC and Kellar KJ. J Pharamcol Exp Ther 275, 1030-1034 (1995).
22. 22. Xiao Y, Meyer EL, Thompson JM et al. Mol Pharmacol 54, 322-333 (1998).
23. 23. Holladay MW, Dart MJ and Lynch JK. J Med Chem 40, 4169-4194 (1997).
24. 24. Clarke PB, Schwartz RD, Paul SM et al. J Neurosci 5, 1307-1315 (1985).
25. 25 Whiting P and Lindstrom J. Proc Natl Acad Sci USA 84, 595-599 (1987).
26. 26. Hulme EC and Birdsall NJM. Receptor Ligand Interactions: A Practical Approach. New York: Oxford University Press, 1992: 63-174.